Embla Medical hf. (CPH:EMBLA)
Denmark
· Delayed Price · Currency is DKK 32.60
-0.30 (-0.91%)
At close: Feb 21, 2025
Embla Medical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 854.89 | 785.68 | 718.65 | 718.67 | 629.5 | Upgrade
|
| Revenue Growth (YoY) | 8.81% | 9.33% | -0.00% | 14.16% | -8.27% | Upgrade
|
| Cost of Revenue | 320.19 | 300.11 | 278.9 | 263.28 | 238.27 | Upgrade
|
| Gross Profit | 534.7 | 485.57 | 439.75 | 455.39 | 391.24 | Upgrade
|
| Selling, General & Admin | 380.12 | 359.97 | 338.59 | 328.03 | 306.95 | Upgrade
|
| Research & Development | 40.83 | 38.14 | 34.02 | 31.74 | 31.02 | Upgrade
|
| Operating Expenses | 420.95 | 398.11 | 372.61 | 359.76 | 337.97 | Upgrade
|
| Operating Income | 113.75 | 87.46 | 67.14 | 95.62 | 53.27 | Upgrade
|
| Interest Expense | -23.25 | -17.96 | -11.2 | -9.8 | -9.61 | Upgrade
|
| Interest & Investment Income | 1.97 | 3.45 | 0.78 | 0.17 | 0.46 | Upgrade
|
| Earnings From Equity Investments | 3.34 | 3.4 | 0.36 | 0.4 | 0.29 | Upgrade
|
| Currency Exchange Gain (Loss) | -4.44 | -0.67 | 2.61 | 1.12 | -5.88 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.19 | 0.33 | -3.51 | -0.87 | -3.86 | Upgrade
|
| EBT Excluding Unusual Items | 91.56 | 76.01 | 56.17 | 86.64 | 34.66 | Upgrade
|
| Merger & Restructuring Charges | -1 | - | - | - | - | Upgrade
|
| Impairment of Goodwill | - | - | - | - | -5.25 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | -5.37 | Upgrade
|
| Asset Writedown | - | - | - | - | -11.33 | Upgrade
|
| Pretax Income | 90.56 | 76.01 | 56.17 | 86.64 | 12.72 | Upgrade
|
| Income Tax Expense | 21.6 | 17.21 | 12.96 | 20.98 | 4.8 | Upgrade
|
| Earnings From Continuing Operations | 68.96 | 58.8 | 43.21 | 65.66 | 7.92 | Upgrade
|
| Minority Interest in Earnings | -0.68 | -0.41 | -0.7 | -1.66 | -1.71 | Upgrade
|
| Net Income | 68.28 | 58.39 | 42.51 | 63.99 | 6.21 | Upgrade
|
| Net Income to Common | 68.28 | 58.39 | 42.51 | 63.99 | 6.21 | Upgrade
|
| Net Income Growth | 16.94% | 37.34% | -33.57% | 929.84% | -90.59% | Upgrade
|
| Shares Outstanding (Basic) | 427 | 420 | 418 | 422 | 422 | Upgrade
|
| Shares Outstanding (Diluted) | 427 | 420 | 418 | 423 | 423 | Upgrade
|
| Shares Change (YoY) | 1.51% | 0.60% | -1.17% | 0.02% | -0.43% | Upgrade
|
| EPS (Basic) | 0.16 | 0.14 | 0.10 | 0.15 | 0.01 | Upgrade
|
| EPS (Diluted) | 0.16 | 0.14 | 0.10 | 0.15 | 0.01 | Upgrade
|
| EPS Growth | 15.20% | 36.53% | -32.78% | 929.72% | -90.55% | Upgrade
|
| Free Cash Flow | 89.03 | 65.09 | 44.22 | 83.57 | 78.47 | Upgrade
|
| Free Cash Flow Per Share | 0.21 | 0.15 | 0.11 | 0.20 | 0.19 | Upgrade
|
| Gross Margin | 62.55% | 61.80% | 61.19% | 63.37% | 62.15% | Upgrade
|
| Operating Margin | 13.31% | 11.13% | 9.34% | 13.31% | 8.46% | Upgrade
|
| Profit Margin | 7.99% | 7.43% | 5.92% | 8.90% | 0.99% | Upgrade
|
| Free Cash Flow Margin | 10.41% | 8.28% | 6.15% | 11.63% | 12.47% | Upgrade
|
| EBITDA | 137.92 | 108.29 | 89.45 | 119.86 | 77.01 | Upgrade
|
| EBITDA Margin | 16.13% | 13.78% | 12.45% | 16.68% | 12.23% | Upgrade
|
| D&A For EBITDA | 24.16 | 20.83 | 22.31 | 24.23 | 23.75 | Upgrade
|
| EBIT | 113.75 | 87.46 | 67.14 | 95.62 | 53.27 | Upgrade
|
| EBIT Margin | 13.31% | 11.13% | 9.34% | 13.31% | 8.46% | Upgrade
|
| Effective Tax Rate | 23.85% | 22.64% | 23.08% | 24.22% | 37.73% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.